COMPASS Pathways, a mental health treatment business, gained the designation for its psilocybin therapy for treatment-resistant depression in 2018. In 2019, Usona Institute, a nonprofit clinical researcher, received the designation to continue its screening of psilocybin as a treatment for key depressive disorder.The opinions expressed are definite